Authors:Bindernagel C, Sotoudeh S, Nguyen M, Wetzstein G, Sriaroon P, Walter J
Published: Front Immunol. 2023;14:1154448
Clinical & Real-World Data
Response to Asceniv Treatment in a Case Series of Patients with Antibody Deficiency and Related Infections Refractory to Conventional Immunoglobulin Replacement Therapy
Authors:Tambay A, Loop L, Siri D, Geng B
Poster presented at: Aspen 2023 Annual Allergy Conference; July 30 - August 3, 2023; Aspen, CO.
In-vivo and Human Evidence for Potential Efficacy of Therapeutic Polyclonal RSV Neutralizing Antibodies for Palivizumab-resistant RSV Infections
Authors:Ramirez KA, Mond J, Papenburg J, Boivin G, Gilbert BE, Falsey AR, Bagga B, DeVincenzo JP
Published: Virology. 2023; 586:115-121
Case Report of Real-World Use of human-slra 10% through Subcutaneous Infusion
Authors:Loop L, Geng B
Poster presented at: The European Academy of Allergy and Clinical Immunology (EAACI) Congress; June 9-11, 2023; Hamburg, Germany
Treatment Response to Unique Blend IVIG with High Titers to RSV and Common Respiratory Pathogens in Patients with Antibody Deficiency and Chronic Lung Disease
Authors:Loop L, Tambay A, Geng B
Poster presented at: The European Academy of Allergy and Clinical Immunology (EAACI) Congress; June 9-11, 2023; Hamburg, Germany
Reductions in Infections and Associated Complications in Nine Common Variable Immunodeficiency Patients Treated with Immune globulin intravenous, human-slra
Authors:Huss J, McNeil D, Melton S, Myers G
Published: Poster presented at: The Eastern Allergy Conference Annual Meeting; June 1-4, 2023; Palm Beach, FL
Case Study: Successful Transition to ASCENIV Therapy with Improved PROMs
Authors:Prosser B, Miller C
Poster presented at: CIS 2023 Annual Meeting; May 18-21, 2023; St Louis, MO
Case Study: Successful Transition to ASCENIV Therapy with Improved PROMs
Authors:Prosser B, Miller C, Walton T
Published: Clin Immunol. 2023;250(Supp):109445
ASCENIV™ utilization in a primary immunodeficiency patient with recurrent viral infections
Authors:Rosenbach KP, Greener BN, Rosenbach JT, Wetzstein GA
Published: Immunol Med. 2023;46(1):58-60
Treatment with intravenous immune globulin 10% in a real-world outpatient setting
Authors:Herrscher R, Rosenbach K, Luu Q, Kim-Romo D, Van Anglen L
Poster presented at: AAAAI 2023 Annual Meeting; February 24-27, 2023; San Antonio, TX
Real-world utilization of immune globulin intravenous 10% at physician office infusion centers
Authors:Herrscher R , Luu Q, Kim-Romo D, Van Anglen L
Poster presented at: ACAAI 2022 Annual Scientific Meeting; November 10-14, 2022; Louisville, KY
Real-world evaluation of immune globulin intravenous 10% in the treatment of primary immunodeficiency
Authors:Van Anglen L, Kim-Romo D
Poster presented at: IgNS 2022 11th National Conference; September 29-October 2, 2022; Washington, DC
Review of ASCENIV in Two Young Males with Immune Abnormalities and RSV-Induced Respiratory Failure: A Case Series
Authors:Bindernagel C, Sullivan S, Miranda MA, Timothy P, Wetzstein G, Sriaroon P, Walter J
Poster presented at: The Florida Allergy, Asthma & Immunology Society (FAAIS) 2022 Annual Meeting; July 15-17, 2022; Orlando, FL
ASCENIV™ reduces viral infections and associated comorbidities in a primary immunodeficiency patient
Authors:Rosenbach K, Greener B, Rosenbach J, Wetzstein G
Poster presented at: CIS 2022 Annual Meeting; March 31-April 3, 2022; Charlotte, NC
Use of ASCENIV™ in a young male with immune abnormalities and multiviral-induced respiratory failure
Authors:Bindernagel C, Sullivan S, Miranda MA, Timothy P, Wetzstein G, Sriaroon P, Walter, J
Poster presented at: AAAAI 2022 Annual Meeting; February 25-28, 2022; Phoenix, AZ
Clinical impact of concomitant use of a novel high-titer immune globulin in an adult with COVID-19 and severe acute respiratory distress syndrome (ARDS)
Authors:Wetzstein GA, Ismail M, Gruenglas J, Decker D, Mond J
Poster presented at: 2021 International Society for Influenza and Other Respiratory Virus Diseases—World Health Organization (ISIRV-WHO) Virtual Conference; October 19-21, 2021
Kinetics of post-vaccination seroprotection to S. pneumoniae for the immune-compromised and vaccine-naïve populations
Authors:Mond J, Scobie M, Tolman C, Gruenglas J, Martinez J
Poster presented at: IDWeek 2021 Virtual Conference; September 29-October 3, 2021
RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations
Authors:Wasserman RL, Greener BN, Mond J
Published: Expert Rev Clin Immunol. 2017;13(12):1107-1119
Efficacy, safety, and pharmacokinetics of a new 10% liquid intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses in subjects with primary immunodeficiency disease
Authors:Wasserman RL, Lumry W, Harris J III, Levy R, Stein M, Forbes L, Cunningham-Rundles C, Melamed I, Kobayashi A, Du W, Kobayashi R
Phase 3 study published: J Clin Immunol. 2016;36(6):590-599
Analysis of specific antibody levels in PIDD patients enrolled in a pivotal trial with an IVIG containing high titer neutralizing antibody to RSV
Authors:Mond J, Orange J, Du W, Kobayashi A, Kobayashi R, Cunningham-Rundles C, Lumry W, Harris J III, Levy R, Stein M, Forbes L, Melamed I, Kestenberg K, Wasserman RL
Poster presented at: CIS 2015 Annual Meeting Immune Deficiency & Dysregulation North American Conference; April 9-12, 2015; Houston, TX